Initiator Pharma A/S
The answer first
Does Initiator Pharma beat the market?
No, Initiator Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 9% of Nordic stocks
- Quality53
- Value1
- Trend26
No. 163 of 195 in healthcare
Max for seven days
Follow Initiator Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Initiator Pharma
Your first answer is free, no account needed.
Do you own Initiator Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Initiator Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- Initiator Pharma has fallen 6.5% over the past year, including dividends.
- Overall, Initiator Pharma ranks better than 9% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 83.2%. The price is 77.8% below its peak now.
What do analysts think of Initiator Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 9% of Nordic stocks.
No. 163 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 119 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity1.54
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−328.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 193 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity13.3
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 112 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−4.7%
- 6 months−20.2%
- 9 months−27.8%
- 12 months−6.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Initiator Pharma
One fund we follow owns Initiator Pharma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Initiator Pharma
Initiator Pharma A/S is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.
Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD).


See the full analysis of Initiator Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card